Revlon refinances
This article was originally published in The Rose Sheet
Executive Summary
Revlon will refinance and replace its existing $800 mil. term loan with a new five-year $840 mil. term loan, company announces Nov. 29. The move supports the firm's previously announced plans to improve cash flow and strengthen its balance sheet. Revlon also will amend its existing $160 mil. revolving credit facility and extend its maturity through the same five-year period. The firm expects its financial decisions to result in lower interest margins, which will lead to annual interest savings, greater financial flexibility and longer maturity dates for existing bank credit agreements, Revlon says. The credit facilities are expected to close by the end of the month. The company is currently $800 mil. in debt; CEO David Kennedy announced his reorganization strategy in November (1"The Rose Sheet" Nov. 13, 2006, p. 3)...
You may also be interested in...
Can Kennedy Right Revlon? Growth Plan Includes Portfolio Review
Newly appointed Revlon CEO David Kennedy said his new growth strategy for the firm will emphasize better life cycle management of older products and the discontinuation of brands that do not meet sales muster
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.